Publicacións nas que colabora con Patricia Ruiz Garbajosa (14)

2024

  1. Deciphering mechanisms affecting cefepime-taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 2, pp. 279-296

  2. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 37, Núm. 1, pp. 69-77

2023

  1. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 6, pp. 360-370

  2. Significant increase of CTX-M-15-ST131 and emergence of CTX-M-27-ST131 Escherichia coli high-risk clones causing healthcare-associated bacteraemia of urinary origin in Spain (ITUBRAS-2 project)

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2291-2296

2022

  1. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 3

2021

  1. A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2677-2699

2018

  1. Comparison of Predictors and Mortality between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae

    Infection Control and Hospital Epidemiology, Vol. 39, Núm. 6, pp. 660-667

  2. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae

    International Journal of Antimicrobial Agents, Vol. 52, Núm. 5, pp. 577-585

2017

  1. Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

    Clinical Infectious Diseases, Vol. 65, Núm. 10, pp. 1615-1623

  2. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

2016

  1. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain

    Journal of Infection, Vol. 72, Núm. 2, pp. 152-160

2015

  1. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 6, pp. 3406-3412

  2. Rates of faecal colonization by carbapenemase-producing enterobacteriaceae among patients admitted to ICUs in Spain

    Journal of Antimicrobial Chemotherapy

2014

  1. La amenaza de las enterobacterias productoras de carbapenemasas en España: Documento de posicionamiento de los grupos de estudio GEIH y GEMARA de la SEIMC

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 10, pp. 666-670